Akanda Corp. (NASDAQ:AKAN – Get Free Report) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 193,393 shares, a growth of 269.9% from the October 15th total of 52,279 shares. Currently, 44.9% of the shares of the stock are short sold. Based on an average trading volume of 609,501 shares, the short-interest ratio is currently 0.3 days.
Wall Street Analysts Forecast Growth
AKAN has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Akanda from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Akanda in a research note on Wednesday. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Akanda has an average rating of “Sell”.
Check Out Our Latest Analysis on Akanda
Akanda Price Performance
Akanda stock traded down $0.02 during trading hours on Thursday, hitting $0.72. The stock had a trading volume of 43,049 shares, compared to its average volume of 1,182,817. The business’s 50 day simple moving average is $1.99 and its 200-day simple moving average is $7.72. Akanda has a one year low of $0.67 and a one year high of $78.90.
Akanda (NASDAQ:AKAN – Get Free Report) last announced its earnings results on Wednesday, September 30th. The company reported ($5.90) EPS for the quarter. The business had revenue of $0.20 million during the quarter.
Akanda Company Profile
Akanda Corporation is an international medical cannabis company focused on the cultivation, processing, distribution and sale of cannabis-based products. Its activities have included supplying medical cannabis flower, oils and other related products to patients, pharmacies, clinics and healthcare providers through regulated markets. The company has historically operated through businesses including Holigen, which was associated with cannabis cultivation and processing in Portugal, and CanMart, a United Kingdom-based importer and distributor of medical cannabis products.
Further Reading
- Five stocks we like better than Akanda
- 3 Pharmaceutical Stocks That Offer Safety and Growth
- If Japan’s Stock Market Rally Returns, These 3 ETFs Could Benefit
- CoreWeave’s Backlog Is Surging—Can the Stock Follow?
- Tesla’s Plan to End Cybertruck Reveals Its Real Priorities
Receive News & Ratings for Akanda Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akanda and related companies with MarketBeat.com's FREE daily email newsletter.
